Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B
Open Access
- 27 December 2012
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 20 (4), e37-e46
- https://doi.org/10.1111/jvh.12025
Abstract
In the phase‐III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2‐year treatment in HBeAg‐positive and HBeAg‐negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%) of telbivudine‐treated patients, who were serum HBV DNA positive or negative and without genotypic resistance to telbivudine at the end of the GLOBE/015 trials, were enrolled into a further 2‐year extension study. A group of 502 patients completed 4 years of continuous telbivudine treatment and were included in the telbivudine per‐protocol population. Amongst 293 HBeAg‐positive patients, 76.2% had undetectable serum HBV DNA and 86.0% had normal serum ALT at the end of 4 years. Notably, the cumulative rate of HBeAg seroconversion was 53.2%. Amongst 209 HBeAg‐negative patients, 86.4% had undetectable HBV DNA and 89.6% had normal serum ALT. In patients who had discontinued telbivudine treatment due to HBeAg seroconversion, the HBeAg response was durable in 82% of patients (median 111 weeks of off‐treatment follow‐up). The cumulative 4‐year resistance rate was 10.6% for HBeAg‐positive and 10.0% for HBeAg‐negative patients. Most adverse events were mild or moderate in severity and transient. Renal function measured by estimated glomerular filtration rate (eGFR) increased by 14.9 mL/min/1.73 m2 (16.6%) from baseline to 4 years (P < 0.0001). In conclusion, in HBeAg‐positive and HBeAg‐negative CHB patients without resistance after 2 years, two additional years of telbivudine treatment continued to provide effective viral suppression with a favourable safety profile. Moreover, telbivudine achieved 53% of HBeAg seroconversion in HBeAg‐positive patients.Keywords
This publication has 27 references indexed in Scilit:
- 515 VIROLOGICAL BREAKTHROUGH AND GENOTYPIC RESISTANCE IN A RANDOMIZED, CONTROLLED STUDY ON TELBIVUDINE TREATMENT APPLYING ROADMAP CONCEPT IN CHB: W76 INTERIM ANALYSIS OF EFFORT STUDYJournal of Hepatology, 2012
- Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis BLiver International, 2011
- Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus InfectionDigestive Diseases and Sciences, 2010
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis BHepatology International, 2008
- Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized ApproachGastroenterology, 2008
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with LamivudineThe Journal of Infectious Diseases, 1999